LncRNA HOXA ‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis

In conclusion, elevated expression of lncRNA HOXA-AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non-small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study. Specifically, the potential of lncRNAHOXA-AS2 as a biomarker in assessing tumor stage, metastasis risk and OS in patients was demonstrated. However, the results of the present study also indicated that the expression of lncRNA HOXA-AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these factors. This insight may direct future research to place more focus on the relationship between lncRNA HOXA-AS2 and specific cancer types and clinical characteristics.PMID:38586205 | PMC:PMC10996033 | DOI:10.3892/ol.2024.14359
Source: Oncology Letters - Category: Cancer & Oncology Authors: Source Type: research